Long acting GLP-1 receptor agonist (injectable)
Liraglutide 1.2 mg subcutaneous once daily
LIRA_SC_1p2MG_QD
Related
- All doses pooled: Liraglutide injection
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.06 (-1.31 to -0.80) | 0.68 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.41 (-0.04 to 0.92) | 0.23 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -0.70 (-2.89 to 2.11) | 0.43 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.13 (-2.18 to -0.11) | 0.62 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.67 (1.64 to 7.32) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.56 (0.03 to 10.76) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Dulaglutide flexible dose injection once weekly | HR 1.23 (0.15 to 10.60) | 0.65 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.13 (0.37 to 3.09) | 0.45 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.63 (-4.66 to -0.61) | 0.57 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 5.81 (-0.22 to 11.67) | 0.21 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -0.26 (-6.98 to 7.12) | 0.24 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.78 (0.37 to 6.62) | 0.24 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.65 (0.25 to 9.52) | 0.18 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.79 (-1.39 to 3.02) | 0.49 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.06 (0.73 to 1.53) | 0.45 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.54 (1.80 to 3.62) | 0.53 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.27 (1.44 to 3.56) | 0.56 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.34 (0.95 to 1.89) | 0.59 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.10 (0.57 to 2.07) | 0.64 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.75 (0.07 to 8.30) | 0.50 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -0.83 (-11.92 to 10.03) | 0.30 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -3.45 (-12.97 to 5.82) | 0.48 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.50 (0.09 to 2.00) | 0.72 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.93 (1.29 to 2.90) | 0.78 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.56 (0.65 to 3.32) | 0.81 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.81 (0.32 to 1.95) | 0.81 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.70 (0.70 to 3.88) | 0.58 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.20 (-0.86 to 0.57) | 0.56 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 1.12 (0.65 to 2.07) | 0.39 |
| Type 1 diabetes | Nausea | longest follow-up | Placebo | HR 3.70 (2.35 to 5.80) | 0.30 |
| Type 1 diabetes | Vomiting | longest follow-up | Placebo | HR 2.71 (1.45 to 5.20) | 0.31 |
| Type 1 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.38 (0.81 to 2.40) | 0.35 |
| Type 1 diabetes | Constipation | longest follow-up | Placebo | HR 2.81 (1.32 to 6.06) | 0.07 |
| Polycystic ovary syndrome | Nausea | longest follow-up | Placebo | HR 1.12 (0.19 to 6.20) | 0.58 |
| Polycystic ovary syndrome | Diarrhea | longest follow-up | Placebo | HR 1.34 (0.16 to 9.98) | 0.61 |
| Polycystic ovary syndrome | Regular menstrual cycles | weeks 12 to 52 (target week 26) | Standard care or no added treatment | OR 1.68 (0.23 to 14.46) | 0.50 |
Trials
- NCT04969627Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.2021 · 60 randomized · 12 weeks
- S0029702019 · 39 randomized · 26.07 weeks
- S0034422019 · 96 randomized · 24 weeks
- S0031522019 · 360 randomized · 24 weeks
- S0030222018 · 60 randomized · 12 weeks
- SUSTAIN 10Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes2017 · 577 randomized · 30 weeks
- LIRAVISShort Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in a Sub Saharan African Population With Type 2 Diabetes2015 · 14 randomized · 2 weeks
- ADJUNCT TWO™A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial2014 · 835 randomized · 26 weeks
- NCT02187250Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome2014 · 45 randomized · 12 weeks
- ADJUNCT ONE™The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial2013 · 1,398 randomized · 52 weeks
- S0030752011 · 52 randomized · 52 weeks
- S0030942011 · 12 weeks
- NCT01911468Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin2011 · 40 randomized · 12 weeks
- NCT00700817The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension2008 · 665 randomized · 26 weeks
- NCT00422058Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period2007 · 564 randomized · 52 weeks
- S0030672007 · 564 randomized · 52 weeks
- LEAD-1Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.2006 · 1,041 randomized · 26 weeks
- LEAD-2Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes2006 · 1,091 randomized · 26 weeks